Patient-focussed outcomes in acromegaly

Pituitary

Volumn 17, Issue SUPPL. 1, 2014, Pages

  Guitelman, Mirtha ^a   Abreu, Alin ^b   Espinosa De Los Monteros, Ana Laura ^c   Mercado, Moíses ^c,d  

^a HOSPITAL DURAND   (Argentina)

^b CENTRO MÉDICO IMBANACO   (Colombia)

^c HOSPITAL DE ESPECIALIDADES   (Mexico)

^d UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Acromegaly; GH; IGF 1; Latin America; Pituitary; Quality of life; Somatostatin analogs

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; GLUCOSE; HYDROCORTISONE; LEVOTHYROXINE; LUTEINIZING HORMONE; PROLACTIN; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; TESTOSTERONE; THYROXINE;

ACROMEGALY; ADULT; ARTICLE; CANCER RADIOTHERAPY; CASE REPORT; CLINICAL FEATURE; DRUG INTERMITTENT THERAPY; ECHOCARDIOGRAPHY; FOLLOW UP; GROWTH HORMONE SECRETING ADENOMA; HUMAN; HYPOGONADOTROPIC HYPOGONADISM; HYPOPHYSIS ADENOMA; HYPOPITUITARISM; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PHYSICAL EXAMINATION; PRIORITY JOURNAL; QUALITY OF LIFE; SKULL SURGERY; SOUTH AND CENTRAL AMERICA; TRANSSPHENOIDAL SURGERY; TREATMENT DURATION; TREATMENT INDICATION;

ACROMEGALY; ADULT; ARTHRALGIA; COMORBIDITY; FATAL OUTCOME; HUMANS; MALE; PATIENT-CENTERED CARE; QUALITY OF LIFE; QUESTIONNAIRES; SLEEP APNEA SYNDROMES;

EID: 84898800204     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-013-0519-8     Document Type: Article

References (46)

1. Rowles SV, Prieto L, Badia X, Shalet SM, Webb SM, Trainer PJ (2005) Quality of life (QOL) in patients with acromegaly is severely impaired: use of a novel measure of QOL: acromegaly quality of life questionnaire. J Clin Endocrinol Metab 90(6):3337-3341 (Pubitemid 41014295)
2. Webb SM (2006) Quality of life in acromegaly. Neuroendocrinology 83(3-4):224-229
3. Katznelson L, Atkinson JL, Cook DM, Ezzat SZ, Hamrahian AH, Miller KK, American Association of Clinical Endocrinologists (2011) American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly-2011 update. Endocr Pract 17(Suppl 4):1-44
4. Webb SM, Prieto L, Badia X, Albareda M, Catalá M, Gaztambide S, Lucas T, Páramo C, Picó A, Lucas A, Halperin I, Obiols G, Astorga R (2002) Acromegaly Quality of Life Questionnaire (ACROQOL) a new health-related quality of life questionnaire for patients with acromegaly: development and psychometric properties. Clin Endocrinol (Oxf) 57(2):251-258 (Pubitemid 34989102)
5. Webb SM, Badia X, Surinach NL; Spanish AcroQol Study Group (2006) Validity and clinical applicability of the acromegaly quality of life questionnaire, AcroQoL: a 6-month prospective study. Eur J Endocrinol 155(2):269-277 (Pubitemid 44269443)
6. Biermasz NR, van Thiel SW, Pereira AM, Hoftijzer HC, van Hemert AM, Smit JW, Romijn JA, Roelfsema F (2004) Decreased quality of life in patients with acromegaly despite long-term cure of growth hormone excess. J Clin Endocrinol Metab 89(11):5369-5376 (Pubitemid 39518410)
7. Biermasz NR, Pereira AM, Smit JW, Romijn JA, Roelfsema F (2005) Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life. J Clin Endocrinol Metab 90(5):2731-2739 (Pubitemid 40686317)
8. Kauppinen-Mäkelin R, Sane T, Sintonen H, Markkanen H, Välimäki MJ, Löyttyniemi E, Niskanen L, Reunanen A, Stenman UH (2006) Quality of life in treated patients with acromegaly. J Clin Endocrinol Metab 91(10):3891-3896 (Pubitemid 44536860)
9. Webb SM (2011) Pituitary tumors: coping with 'cured' pituitary tumors. Nat Rev Endocrinol 7(5):251-252
10. Tiemensma J, Kaptein AA, Pereira AM, Smit JW, Romijn JA, Biermasz NR (2011) Coping strategies in patients after treatment for functioning or nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 96(4):964-971
11. Celik O, Kadioglu P (2013) Quality of life in female patients with acromegaly. J Endocrinol Invest 36:412-416
12. T'Sjoen G, Bex M, Maiter D, Velkeniers B, Abs R (2007) Health-related quality of life in acromegalic subjects: data from AcroBel, the Belgian registry on acromegaly. Eur J Endocrinol 157(4):411-417
13. van der Klaauw AA, Kars M, Biermasz NR, Roelfsema F, Dekkers OM, Corssmit EP, van Aken MO, Havekes B, Pereira AM, Pijl H, Smit JW, Romijn JA (2008) Disease-specific impairments in quality of life during long-term follow-up of patients with different pituitary adenomas. Clin Endocrinol (Oxf) 69(5):775-784
14. Marko NF, Lasota E, Hamrahian AH, Weil RJ (2012) Comparative effectiveness review of treatment options for pituitary microadenomas in acromegaly. J Neurosurg 117(3):522-538
15. Siegel S, Streetz-van der Werf C, Schott JS, Nolte K, Karges W, Kreitschmann-Andermahr I (2012) Diagnostic delay is associated with psychosocial impairment in acromegaly. Pituitary. doi:10.1007/s11102-012-0447-z
16. Trepp R, Everts R, Stettler C, Fischli S, Allemann S, Webb SM, Christ ER (2005) Assessment of quality of life in patients with uncontrolled vs. controlled acromegaly using the Acromegaly Quality of Life Questionnaire (AcroQoL). Clin Endocrinol (Oxf) 63(1):103-110 (Pubitemid 40966410)
17. Hua SC, Yan YH, Chang TC (2006) Associations of remission status and lanreotide treatment with quality of life in patients with treated acromegaly. Eur J Endocrinol 155(6):831-837
18. Matta MP, Couture E, Cazals L, Vezzosi D, Bennet A, Caron P (2008) Impaired quality of life of patients with acromegaly: control of GH/IGF-I excess improves psychological subscale appearance. Eur J Endocrinol 158(3):305-310 (Pubitemid 351404993)
19. Ben-Shlomo A, Sheppard MC, Stephens JM, Pulgar S, Melmed S (2011) Clinical, quality of life, and economic value of acromegaly disease control. Pituitary 14(3):284-294
20. Wexler T, Gunnell L, Omer Z, Kuhlthau K, Beauregard C, Graham G, Utz AL, Biller B, Nachtigall L, Loeffler J, Swearingen B, Klibanski A, Miller KK (2009) Growth hormone deficiency is associated with decreased quality of life in patients with prior acromegaly. J Clin Endocrinol Metab 94(7):2471-2477
21. Miller A, Doll H, David J, Wass J (2008) Impact of musculoskeletal disease on quality of life in long-standing acromegaly. Eur J Endocrinol 158(5):587-593 (Pubitemid 351639595)
22. Psaras T, Honegger J, Gallwitz B, Milian M (2011) Are there gender-specific differences concerning quality of life in treated acromegalic patients? Exp Clin Endocrinol Diabetes 119(5):300-305
23. Wassenaar MJ, Biermasz NR, Kloppenburg M, van der Klaauw AA, Tiemensma J, Smit JW, Pereira AM, Roelfsema F, Kroon HM, Romijn JA (2010) Clinical osteoarthritis predicts physical and psychological QoL in acromegaly patients. Growth Horm IGF Res 20(3):226-233
24. Killinger Z, Kužma M, Sterančáková L, Payer J (2012) Osteoarticular changes in acromegaly. Int J Endocrinol 2012:839282
25. Orük G, Tarhan F, Argin M, Ozmen M (2013) Is every joint symptom related to acromegaly? Endocrine 43(2):404-411
26. Davì MV, Giustina A (2012) Sleep apnea in acromegaly: a review on prevalence, pathogenetic aspects and treatment. Expert Rev Endocrinol Metab 7(1):55-62
27. van der Klaauw AA, Biermasz NR, Hoftijzer HC, Pereira AM, Romijn JA (2008) Previous radiotherapy negatively influences quality of life during 4 years of follow-up in patients cured from acromegaly. Clin Endocrinol (Oxf) 69(1):123-128 (Pubitemid 351847272)
28. Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Vandenbroucke JP (2008) Mortality in acromegaly: a meta-analysis. J Clin Endocrinol Metab 93(1):61-67
29. Holdaway IM, Rajasoorya RC, Gamble GD (2004) Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89(2):667-674 (Pubitemid 38269875)
30. Sonino N, Scarpa E, Paoletta A, Fallo F, Boscaro M (1999) Slow-release lanreotide treatment in acromegaly: effects on quality of life. Psychother Psychosom 68(3):165-167 (Pubitemid 29209822)
31. Gilbert J, Ketchen M, Kane P, Mason T, Baister E, Monaghan M, Barr S, Harris PE (2003) The treatment of de novo acromegalic patients with octreotide-LAR: efficacy, tolerability and cardiovascular effects. Pituitary 6(1):11-18 (Pubitemid 37455640)
32. Colao A, Cappabianca P, Caron P, De Menis E, Farrall AJ, Gadelha MR, Hmissi A, Rees A, Reincke M, Safari M, T'Sjoen G, Bouterfa H, Cuneo RC (2009) Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, openlabel, multicentre study. Clin Endocrinol (Oxf) 70(5):757-768
33. Lombardi G, Minuto F, Tamburrano G, Ambrosio MR, Arnaldi G, Arosio M, Chiarini V, Cozzi R, Grottoli S, Mantero F, Bogazzi F, Terzolo M, Tita P, Boscani PF, Colao A (2009) Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in somatostatin analogue-naive patients with acromegaly. J Endocrinol Invest 32(3):202-209
34. Sardella C, Lombardi M, Rossi G, Cosci C, Brogioni S, Scattina I, Webb SM, Gasperi M, Martino E, Bogazzi F (2010) Short- and long-term changes of quality of life in patients with acromegaly: results from a prospective study. J Endocrinol Invest 33(1):20-25
35. Karaca Z, Tanriverdi F, Elbuken G, Cakir I, Donmez H, Selcuklu A, Durak AC, Dokmetas HS, Colak R, Unluhizarci K, Kelestimur F (2011) Comparison of primary octreotide-lar and surgical treatment in newly diagnosed patients with acromegaly. Clin Endocrinol (Oxf) 75(5):678-684
36. Neggers SJ, van Aken MO, de Herder WW, Feelders RA, Janssen JA, Badia X, Webb SM, van der Lely AJ (2008) Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. J Clin Endocrinol Metab 93(10):3853-3859
37. Postma MR, Netea-Maier RT, van den Berg G, Homan J, Sluiter WJ, Wagenmakers MA, van den Bergh AC, Wolffenbuttel BH, Hermus AR, van Beek AP (2012) Quality of life is impaired in association with the need for prolonged postoperative therapy by somatostatin analogs in patients with acromegaly. Eur J Endocrinol 166(4):585-592
38. Bevan JS, Newell-Price J, Wass JA, Atkin SL, Bouloux PM, Chapman J, Davis JR, Howlett TA, Randeva HS, Stewart PM, Viswanath A (2008) Home administration of lanreotide Autogel by patients with acromegaly, or their partners, is safe and effective. Clin Endocrinol (Oxf) 68(3):343-349 (Pubitemid 351257850)
39. Salvatori R, Nachtigall LB, Cook DM, Bonert V, Molitch ME, Blethen S, Chang S, SALSA Study Group (2010) Effectiveness of self- or partner- administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naïve patients with acromegaly. Pituitary 13(2):115-122
40. Salvatori R, Woodmansee WW, Molitch M, Gordon MB, Lomax KG (2013) Lanreotide extended-release aqueous-gel formulation, injected by patient, partner or healthcare provider in patients with acromegaly in the United States: 1-year data from the SODA registry. Pituitary. doi:10.1007/s11102-012-0460-2
41. Carmichael JD (2012) Lanreotide depot deep subcutaneous injection: a new method of delivery and its associated benefits. Patient Prefer Adherence 6:73-82
42. Johanson V, Wilson B, Abrahamsson A, Jianu C, Calissendorff J, Wall N, Grønbæk H, Florholmen J, Ohberg A, Granberg D (2012) Randomized crossover study in patients with neuroendocrine tumors to assess patient preference for lanreotide Autogel(®) given by either self/partner or a health care professional. Patient Prefer Adherence 6:703-710
43. Schopohl J, Strasburger CJ, Caird D, Badenhoop K, Beuschlein F, Droste M, Plöckinger U, Petersenn S, German Lanreotide Study Group (2011) Efficacy and acceptability of lanreotide Autogel® 120 mg at different dose intervals in patients with acromegaly previously treated with octreotide LAR. Exp Clin Endocrinol Diabetes 119(3):156-162
44. Neggers SJ, Biermasz NR, van der Lely AJ (2012) What is active acromegaly and which parameters do we have? Clin Endocrinol (Oxf) 76(5):609-614
45. Bevan JS (2005) Clinical review: the antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 90(3):1856-1863
46. Garduño-Perez AA, Zamarripa-Escobedo R, Vergara-Lopez A, Guillen-Gonzalez MA, Escudero-Licona I (2011) Análisis de la calidad de vida en pacientes con acromegalia en el Centro Medico Nacional 20 de Noviembre, ISSSTE. Rev Endocrinol Nutr 19:97-101